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Background/aim: Adipokines play an important role in the regulation of metabolism. In critical illness, they alter serum levels and are
suspected to worsen clinical outcomes. But the effect of the route of nutrition on adipokines is not known. The purpose of this study
was to evaluate the association between the route of nutrition and adipokine levels in critically ill patients.
Materials and methods: This prospective study was performed in an intensive care unit (ICU). Patients admitted to the ICU for least
72 h and receiving either enteral nutrition (EN) via tube feeding or parenteral nutrition (PN) were enrolled. Serum was obtained at
baseline, 24 h, and 72 h for concentrations of leptin, adiponectin, resistin, glucagon–like peptide 1 (GLP–1), insulin–like growth factors
1 (IGF–1), and ghrelin.
Results: A total of 26 patients were included in the study. Thirteen patients received EN and 13 patients received PN. In the PN group,
leptin level significantly increased (P = 0.037), adiponectin and ghrelin significantly decreased during follow up (P = 0.037, P = 0.008,
respectively). There was no significant change between all adipokines in the EN group and resistin, IGF–1 and GLP–1 in the PN group
during follow up. Resistin levels were markedly lower in the EN group at both 24 h (P = 0.015) and 72 h (P = 0.006) while GLP–1 levels
were higher in the EN group at baseline, 24 h, and 72 h (P = 0.018, P = 0.005, and P = 0.003, respectively). There were no differences in
leptin, adiponectin, IGF–1, and ghrelin levels over time.
Conclusion: The delivery of EN in critical illness was associated with decreased resistin levels and increased GLP–1 levels. Thus, the
route of nutrition may impact the clinical outcome in critical illness due to adipokines.
Key words: Adipokine, critical illness, enteral nutrition, parenteral nutrition.

1. Introduction
Adipose tissue, a dynamic endocrine organ, is composed
of adipokines, which have a number of biologically active
proteins [1]. Adipokines play a significant role in the
regulation of appetite and satiety, energy expenditure,
fat distribution, insulin sensitivity and secretion,
inflammation and acute-phase responses, immunity,
blood pressure, homeostasis, and endothelial functions
[2]. Many adipokines have been identified, and leptin,
adiponectin, resistin, glucagon–like peptide 1 (GLP–1),
insulin–like growth factors 1 (IGF–1), and ghrelin are the
most closely studied [3].

Adipose tissue might have an important role in the
adaptation to critical illness, which is a multifactorial
heterogeneous disease accompanied by inflammation
and insulin resistance. It changes the secretory function
and leads to major changes in adipokine levels [4].
Therefore, adipokines are suspected of affecting clinical
outcomes in critical illness [3,5,6]. At present, the effect
of some adipokines in critical illness is debated but many
studies have shown that adipokines may cause metabolic
alterations depending on changes in morphological,
physiological, and metabolic functions in adipose tissue
due to critical illness [7–12].
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When oral intake is not possible and the gastrointestinal
system is functional in critically ill patients, EN should
be preferred. If oral and EN are contraindicated, PN
is performed in critically ill patients [13]. EN prevents
intestinal villus atrophy, protects against ischemic
reperfusion injury by stimulating intestinal perfusion,
reduces bacterial permeability, and prevents the
development of systemic infection and multi-organ failure
by protecting intestinal barriers in critically ill patients
[14]. EN affects direct intestinal adipose tissue especially
related to the incretin effect, which is responsible for
adipokines such as GLP–1 and glucose–dependent insulin
tropic peptide (GIP) [15,16]. Hence, adipokines are
thought to be a pathway for the therapeutic benefits of EN
[17]. In a study conducted on patients undergoing ileum
resection due to intestinal injury in Crohn’s disease, it
was reported that EN contributed adipocyte morphology
restoration and reduced inflammation in mesenteric fat
tissue [18].
The effects of EN and PN on circulating adipokines
have not been studied well in critically ill patients. The aim
of this pilot study was to investigate the effects of EN and
PN on these hormones in critically ill patients.
2. Materials and methods
The present study was performed prospectively in the
Medical and Surgical ICU. This study was approved by the
local Ethics Committee and all patients provided informed
consent. This study was a prospective, observational, and
single–centered pilot study with secondary analysis of the
association between refeeding hypophosphatemia and
serum appetite-regulating hormone levels in critically ill
patients.
Patients aged ≥ 18 years and admitted to the ICU
for at least 72 h and who received nutrition support via
EN or PN were included in this study. Patients with
hypophosphatemia (serum phosphorus level ≤ 2.4
mg/L), chronic renal failure, diabetic ketoacidosis, or
hyperparathyroidism at the onset of nutrition, undergoing
treatment for chronic liver disease or biliary tract diseases
(except cholecystectomy), or gastric bypass surgery were
excluded from the study.
Patient demographic characteristics, the reason for
ICU admission, APACHE–II score, SOFA score, Charlson
comorbidities score, and Nutrition Risk in the Critically
İll Score (NUTRIC score) were recorded upon ICU
admission. IR was evaluated by using the HOMA model
[HOMA-IR = fasting insulin (µIU / mL) × fasting glucose
(mmol/L)/ 22.5] [19]. Additionally, the route of nutrition,
daily calorie intake and content and time to feeding of
patients were recorded. The PN group accepted patients
who received PN and the EN group accepted patients who
received EN.
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Blood samples were collected in order to measure
serum leptin, resistin, adiponectin, GLP–1, IGF–1 and
ghrelin at baseline, 24 h, and 72 h. Blood samples were
processed with Trasylol, an inhibitor of pancreatic trypsin
in order to prevent degradation of peptide hormones by
pancreatic trypsin.
Nutrition initiation time and type, target calorie
requirement, and, enteral/parenteral product selection
were set according to ESPEN guidelines after ICU
admission [20]. Patients were given 20–25 kcal/kg/d
energy in acute phase of illness, and 25–30 kcal / kg/d
energy in chronic phase of the illness. Each patient
received only EN or only PN.
Patients with normal gastrointestinal function
received EN. Nutrition therapy was started with 10
mL/h. The nutritional goal was reached by increasing
by 10 mL/4 h. Patients were routinely given standard
enteral formula. Some patients were given a high–fat,
low–carbohydrate enteral formula, a low–volume, high–
energy enteral formula, and a diabetes specific formula for
treatment.
PN was given if EN was contraindicated due to
disturbed gastrointestinal function. For PN, standard
commercial products were used. Compounder TPN was
prepared to different content–carbohydrates (50–60%),
protein (15–20%), fat (20–30%) of calories all in one bag
in our hospital.
Serum adipokines were analyzed at 3 time
points (baseline, 24 h, and 72 h) by enzyme–linked
immunosorbent assay (ELISA) for leptin (DiaSource,
Belgium), adiponectin (Biovendor, Czech Republic),
resistin (Biovance Technologies, USA), GLP–1 (Ray
Biotech, USA), and ghrelin (Phoenix, USA). IGF–1 was
analyzed with the autoanalyzer in the hormone laboratory.
2.1. Statistical analysis
Statistical analysis was conducted using IBM SPSS
Statistics 22 (IBM Corp., Armonk, NY, USA). Categorical
data are presented as n (%), continuous data as median
(interquartile range [IQR]). Categorical data were
compared between 2 groups using the chi-square exact
test. Continuous data were compared between 2 groups
using Mann Whitney U test. Friedman test was used to
determine the serum adipokines levels period. Differences
were considered statistically significant at P > 0.05.
3. Results
A total of 26 patients were included in this study. There
were nine (35%) females and 17 (65%) males. The median
age was 69 (53–75) years. Patient demographic data are
presented in Table 1. The median APACHE-II score was
24 (17–28) and the median SOFA score was 4.0 (0–13.0) at
admission to ICU (Table 1).
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Table 1. Patient demographic and clinical characteristics.
Variables

Total
(n = 26)

EN group
(n = 13)

PN group
(n = 13)

P

Age (year), median (IQR)

69 (53–75)

69 (44–76)

68 (56–75)

0.685

Sex, n (%)
Male
Female

17 (65)
9 (35)

9 (64)
5 (36)

8 (67)
4 (33)

1

Body Mass Index (kg/m2), median (IQR)

27 (22–33)

26 (23–28)

27 (22–33)

0.153

ICU admission type, n (%)
Medical
Surgery

17 (65)
9 (35)

10 (71)
4 (29)

7 (58)
5 (42)

0.986

Reason for ICU admission, n (%)
Malignancy
Sepsis
Neurological disorders
Trauma
Intoxication
Respiratory failure
Gastrointestinal bleeding

9 (35)
5 (19)
5 (19)
3 (12)
2 (7)
1 (4)
1 (4)

2 (15)
2 (15)
5 (39)
2 (15)
1 (8)
1 (8)
0

7 (54)
3 (22)
0
1 (8)
1 (8)
0
1 (8)

0.043

Insulin resistance, n (%)

13 (50)

5 (39)

8 (62)

0.434

Charlson comorbidity index, median (IQR)

3 (0–8)

2 (0–8)

4 (0–8)

0.287

APACHE II score, median (IQR)

24 (17–28)

22 (17–28)

25 (18–28)

0.633

SOFA score, median (IQR)

4.0 (0–13.0)

3.0 (0–13.0)

4 (0–13.0)

0.880

NUTRIC score, median (IQR)

4 (3–5)

5 (3–5)

4 (3–5)

0.011

Length of hospital stay (day), median (IQR)

31 (8–150)

34 (8–125)

28 (9–150)

0.169

Length of ICU stay (day), median (IQR)

20 (2–125)

27 (2–125)

13 (2–45)

0.179

Mortality, n (%)

14 (54)

9 (69)

5 (38)

0.238

APACHE II, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment, Nutrition Risk
Screening–2002.

A total of 13 patients (50%) received EN via feeding
tube and 13 patients (50%) received PN during the 3–day
period of observation. In the EN group, nutrition was
temporarily interrupted in 3 patients due to high gastric
residual volumes and in 1 patient due to tracheostomy.
The target calorie requirement, daily energy intake, and
macronutrient content (the composition of carbohydrate,
protein, and lipid in the EN group; the composition of
glucose, amino acid, and lipid in the PN group) of the
patients are shown in Table 2.
In the PN group, the leptin level significantly increased
(P = 0.037); adiponectin and ghrelin significantly decreased
during follow up (P = 0.037, P = 0.008, respectively). There
was no significant change between all adipokines in the
EN group and resistin, IGF–1 and GLP–1 in the PN group
during follow up (Table 3).
Serial serum adipokine levels in the EN and PN groups
are presented in Figure. There was no difference between

the EN and PN groups for serum leptin, adiponectin,
IGF–1, and ghrelin levels at baseline, 24 h, or 72 h.
Serum resistin levels at 24 h and 72 h were significantly
lower in the EN group compared to the PN group (P =
0.014, P = 0.005, respectively; Figure). However, there was
no significant difference between the EN and PN groups
in serum resistin levels at baseline. In contrast, serum
GLP–1 levels in the EN group were significantly higher at
baseline, 24 h, and 72 h compared to the PN group (P =
0.016, P = 0.004, P = 0.002, respectively; Figure).
4. Discussion
This pilot study was conducted to investigate the
relationship between serum adipokine levels and the
route of nutrition in a mixed cohort of adult critically ill
patients. We determined that the leptin level significantly
increased, adiponectin and ghrelin significantly decreased
during follow up in PN group, and there were decreased
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Table 2. Time to feeding, target calorie requirement, daily calorie intake, percentage energy intake/ requirement, daily carbohydrate/
glucose, total protein/amino acid, and lipid delivered for the EN and PN groups.
Variables

Total
(n = 26)

EN group
(n = 13)

PN group
(n = 13)

P

Time to feeding (h), median (IQR)

24 (20–48)

24 (17–35)

26 (23–62)

0.155

Target calorie requirement (kcal), median (IQR)

1600 (1400–1856)

1750 (1365–1937)

1600 (1400–1800)

0.515

EN product, n (%)
Standard enteral formula
High–fat, low–carbohydrate enteral formula
Low–volume, high–energy enteral formula
Diabetes specific formula
PN product
TPN (with compounder)
TPN (commercial PN products)

6 (46.2)
4 (30.8)
1 (11.0)
1 (11.0)
1 (11.0)

11 (84.6)
2 (14.4)

Daily calorie intake (kcal), median (IQR)
Day 1
Day 2
Day 3

1188 (1053–1375)
1592 (1272–1856)
1474 (1200–1811)

1105 (946– 1323)
1750 (1296–1911)
1474 (1061–1885)

1275 (1122–1386)
1584 (1200–1700)
1600 (1200–1700)

0.219
0.799
0.676

Percentage energy intake / requirement
Day 1
Day 2
Day 3

74.8 (67.6–86.6)
100.0 (98.0–100.0)
100.0 (90.0–100.0)

74.6 (54.4–81.6)
99.4 (96.8–100)
98.2 (77.4–100)

83.9 (68.4–100)
99.5 (99.0–100)
100 (100–100)

0.173
0.190
0.058

Daily carbohydrate/glucose delivered (g/d), median (IQR)
Day 1
Day 2
Day 3

137.5 (96.8–163.6) 106.5 (77.7–130.5) 159.7 (138.9–170.6) 0.002
162.4 (133.6–200.0) 142.2 (106.6–198.0) 186.5 (152.5–200.0) 0.057
142.2 (81.6–200.0) 90.7 (56.6–140.4)
187.5 (152.5–200.0) 0.001

Daily protein/amino acid delivered (g/d), median (IQR)
Day 1
Day 2
Day 3

55.0 (45.8–67.6)
72.5 (55.1–87.4)
72.4 (51.8–81.0)

48.7 (44.3–65.1)
72.5 (53.9–89.6)
72.4 (47.2–85.3)

61.9 (53.4–68.2)
74.6 (57.1–80.0)
75.0 (52.5–80.0)

0.175
0.977
0.552

Daily lipid delivered (g/d), median (IQR)
Day 1
Day 2
Day 3

44.5 (37.6–47.5)
53.3 (45.7–71.5)
53.3 (40.0–68.0)

45.1 (38.3–62.6)
70.6 (52.0–93.4)
56.4 (41.4–93.4)

41.3 (37.0–45.5)
49.7 (40.0–53.3)
50.0 (40.0–53.3)

0.269
0.038
0.177

resistin levels as described in catabolic hormones and
increased GLP–1 levels as described in anabolic hormones
in the EN group.
Leptin levels are usually increased due to the rise
in endotoxins, certain cytokines, and glucocorticoids
in critical illness, although studies of leptin levels are
conflicting [4,21]. Leptin is also described as an indicator
of fasting or malnutrition [22]. The level of leptin in
critical illness is contradictory in the literature, leptin
levels were increasing during follow-up in both groups.
In a study, critical patients who were received continuous
enteral nutrition were followed for 14 days. Similarly to
our findings, the level of leptin increased during follow
up, but was higher than our patients [23]. In our study,
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the PN group had higher malnutrition risk than the EN
group according to the NUTRIC score. Consequently, we
observed that leptin levels in the EN group were higher
than the PN group for the three-time points even if
statistically nonsignificant.
In critical illness, glucose homeostasis is often impaired
and insulin resistance is a common condition due to the
presence of hyperglycemia and hyperinsulinemia. Lower
adiponectin and leptin levels may contribute to insulin
resistance [24]. While it was contradictory in the EN group,
it decreased significantly during the follow-up in the PN
group (P < 0.05) in our study. Also, insulin resistance was
higher in the PN group. As expected, serum adiponectin
and leptin levels in the PN group were relatively lower
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Table 3. Serum adipokines levels at baseline, 24 h, and 72 h to EN group and PN group.
EN group
(n = 13)

PN group
(n = 13)

Baseline

24 h

72 h

P

Baseline

24 h

72 h

P

Leptin (ng / mL), median (IQR)

2.0
(1.3–6.7)

2.5
(1.8–5.6)

3.8
(2.1–8.9)

0.092

1.3
(0.7–2.4)

2.3
(0.6–4.1)

2.3
(1.3–3.9)

0.037

Adiponectin (ng / mL), median (IQR)

25.2
(15.0–37.9)

20.2
(16.6–33.2)

28.6
(19.9–53.2)

0.368

32.9
(23.2–44.4)

25.9
(15.1–31.1)

21.7
(15.4–33.1)

0.037

Resistin (ng /mL), median (IQR)

905.6
594.9
693.6
1373.3
1615.2
1543.4
0.063
0.794
(589.8–1393.3) (354.7–861.8) (464.5–931.7)
(973.0–3332.3) (808.5–2532.9) (882.5–2183.6)

IGF–1 (ng/ mL), median (IQR)

85.6
(65.2–96.7)

43.9
(28.2–73.5)

55.3
(28.0–78.5)

0.098

52.7
(29.3– 88.1)

40.7
(27.3–74.0)

32.2
(25.0–66.6)

0.913

GLP–1 (pg/ mL), median (IQR)

3.1
(2.3–5.5)

5.0
(2.5–13.1)

4.8
(2.3–39.1)

0.232

0.6
(0.4–2.8)

0.9
(0.5–3.5)

0.7
(0.5–3.2)

0.662

Ghrelin (ng /mL), median (IQR)

1.1
(0.9–1.3)

1.0
(0.9–1.3)

1.2
(1.0–1.6)

0.500

1.2
(1.0–1.4)

1.2
(1.1–1.4)

1.0
(0.9–1.2)

0.008

than in the EN group. Resistin is related to inflammation
induced insulin resistance and is increased in critical
illness. But, serum resistin levels was relatively decreasing
in EN group, it was increasing in PN group and EN
group were significantly lower than in the PN group (P <
0.05). We believe that these are due to the incretin effect
associated with EN. McKenzie et al. evaluated adipokine
levels in patients with acute pancreatitis and received EN
during the first 72 h after hospital admission. Similar to
our study, leptin and adiponectin levels increased, while
the level of resistin decreased [17].
GLP–1, 1 of the 2 known incretins, is known to have
increased release with EN. Its levels increased in both
group during the follow-up and were determined higher
in the EN group (P < 0.05). Similar to our study, several
previous studies have also reported elevated GLP–1 in
patients who received EN in critical illness [16,25]. This
data may provide evidence based on nonnutritional effects
of EN and superiority to PN with the incretin effect.
IGF–1 is a sensitive indicator of nutritional condition
and inflammation and is decreased in cases of insufficient
nutrition and presence of critical illness. In the present
study, serum IGF–1 levels decreased in both groups
and were lower in the EN group than in the PN group,
significantly. We considered that this was associated
with the daily calorie intake. The percentage energy
intake requirement in the PN group was higher than in
the EN group in our study because EN was frequently
interrupted for various reasons (nutrition intolerance,
diagnosis, treatment interventions). Therefore, it is easier
to reach the target calorie requirement with PN [16,26].
Similarly, Isley et al. observed in a study of 15 patients that
IGF–1 levels increased with sufficient energy and protein
support. They reported a temporary decrease followed

by an increase in IGF–1 levels after administering low
protein content nutrition with normal caloric levels. They
observed a decrease in IGF–1 levels in cases of insufficient
nutrition [27].
There was an increase in ghrelin levels in the EN group
and, significantly, a decrease in the PN group with an
extended duration of nutrition. Both groups had similar
serum ghrelin levels at baseline. Similar to our study, in
a study conducted in critical patients fed enterally, the
level of ghrelin increased in a similar follow up period.
However, the level of ghrelin was lower in our patients [23].
Because the increase in the EN group might be associated
with the release of ghrelin by gastric oxyntic cells. Enteral
nutrition might therefore, trigger ghrelin secretion more
effectively than PN. Similar to our study, Hagiwara et al.
conducted a study with 4 groups of 15 rodents each, who
received total enteral nutrition conventional (TEN - C),
total enteral nutrition immunonutrition (TEN-I), total
parenteral nutrition (TPN), and saline. The daily calorie
intake of all groups was approximately similar. The study
observed that ghrelin levels were lower in PN compared
to EN [28].
Although the role of adipokines in critical illness is not
understood clearly, significant alterations of circulating
adipokines may be associated with poor clinical outcomes
in critically ill patients. Even though conclusive evidence
that leptin and adiponectin lead to poor clinical outcomes
(increased mortality, inflammation, and development of
multiple organ dysfunction syndromes) is not provided,
some studies present the existence of this relationship
[29,30]. In all studies of resistin, increased levels of blood
resistin are powerfully associated with severe inflammation
and increased risks of organ failure and mortality [31–33].
High ghrelin levels are accepted as a positive predictor
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1.25
1.2
1.15
1.1
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GLP-1, ng/mL
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2
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0
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Figure. Serial serum adipokine levels in the EN and PN group. P < 0.05, Insulin -like growth factors 1 (IGF -1);
GLP-1, Glucagon -like peptide 1 (GLP -1).

of ICU survival and decreased ghrelin levels can lead to
inflammation and length of mechanical ventilation stay
[4]. Clinical outcomes due to adipokine levels may differ
in artificial nutrition (EN or PN). Although most of our
data were not statistically significant, it was shown that
EN increases anabolic hormones and reduces catabolic
hormones in critical illness. In addition, the delivery of EN
was associated with a lower level of hormones that cause
insulin resistance.
This study had several limitations, including the
single–center design, a relatively small number of
patients, heterogeneous study groups, and a lack of
follow up of clinical outcome (mechanical ventilation
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stay, inflammation, etc.). However, its strengths were the
comprehensive panel of adipokines and the first look, to
our knowledge, at the route of nutrition in these hormonal
responses in ICU patients.
In conclusion, this study indicates that EN may help
to correct abnormal processes in critically ill patients by
decreasing resistin levels and increasing GLP–1 levels.
Adipokines may be associated with poor clinical outcomes
of critically ill patients, including higher inflammation,
greater risk of organ dysfunction, and mortality. The
importance of nutrition for normal adipokine levels in
critically ill patients is an indisputable fact. At this point,
the route of nutrition can be an important key. We

GÜNDOĞAN et al. / Turk J Med Sci
conclude that the nonnutritional effects of EN and its
relationship with the incretin effect should not be ignored.
Therefore, the relationship between adipokines and
nutrition should be clarified. Further studies with a larger
number of patients are necessary to choose the nutrition
type that can lead to the least complications.
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